Credit Suisse’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Credit Suisse’s Portfolio STSA Stock Details STSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-72,588	Closed	-$429K	–	4673
2021 Q1	$429K	Sell	72,588 -98,602	-58%	-$597K	﹤0.01%	3864
2020 Q4	$789K	Buy	171,190 +31,717	+23%	+$137K	﹤0.01%	3507
2020 Q3	$543K	Buy	+139,473	New	+$2.8M	﹤0.01%	3340
2020 Q2	–	Sell	-54,296	Closed	-$1.17M	–	4198
2020 Q1	$1.17M	Buy	54,296 +326	+0.6%	+$7.4K	﹤0.01%	2541
2019 Q4	$1.06M	Sell	53,970 -254,614	-83%	-$3.62M	﹤0.01%	3073
2019 Q3	$4.63M	Buy	+308,584	New	+$4.79M	﹤0.01%	1814

Other funds holding STSA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse's STSA Position: Q2 2021 in Review

Credit Suisse sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2021, closing a stake of 72,588 shares — an estimated $429K sold.

Credit Suisse first reported a position in STSA in Q3 2019 and held it in 6 quarters. The position peaked at $4.63M in Q3 2019. 60 funds tracked by Wall St. Rank hold STSA as of Q2 2021.

Credit Suisse reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Credit Suisse sold 72,588 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $429K.
Credit Suisse first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 6 quarters.
Credit Suisse's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $4.63M in Q3 2019.
60 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Credit Suisse's 13F filing for Q2 2021, filed 16 Aug 2021.